Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay K Nooka

Showing results (21-30 of 150) with videos related to

Pageof 15
Sort By:
Journal of Medical Case Reports|August 16, 2011
Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case reportMariam Rauf, Charise Gleason, Ajay K Nooka, et al.
Future Oncology (London, England)|August 24, 2018
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myelomaSarah Chehab, Elyse Hall Panjic, Charise Gleason, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 2, 2017
High-risk Multiple Myeloma: Definition and ManagementNisha S Joseph, Silvia Gentili, Jonathan L Kaufman, et al.
British Journal of Haematology|February 29, 2024
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 1, 2014
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case seriesAjay K Nooka, R Donald Harvey, Amelia Langston, et al.
Cancer|July 13, 2016
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participationAjay K Nooka, Madhusmita Behera, Sagar Lonial, et al.
Acta Haematologica|May 12, 2024
Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory DrugsJulie Barberio, Timothy L Lash, Ajay K Nooka, et al.
Oncotarget|August 4, 2016
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylationShardule P Shah, Ajay K Nooka, David L Jaye, et al.
Journal of Oncology Practice|July 12, 2018
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and ElotuzumabAjay K Nooka, Charise Gleason, Marva Ollivierre Sargeant, et al.
Hemasphere|September 25, 2025
The impact of reduced dosing frequency of elranatamab on patient-reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-3Nizar J Bahlis, Ajay K Nooka, Marco DiBonaventura, et al.
Pageof 15

Showing results (21-30 of 150) with videos related to

Sort By:
Pageof 15
Journal of Medical Case Reports|August 16, 2011
Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case reportMariam Rauf, Charise Gleason, Ajay K Nooka, et al.
Future Oncology (London, England)|August 24, 2018
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myelomaSarah Chehab, Elyse Hall Panjic, Charise Gleason, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 2, 2017
High-risk Multiple Myeloma: Definition and ManagementNisha S Joseph, Silvia Gentili, Jonathan L Kaufman, et al.
British Journal of Haematology|February 29, 2024
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 1, 2014
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case seriesAjay K Nooka, R Donald Harvey, Amelia Langston, et al.
Cancer|July 13, 2016
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participationAjay K Nooka, Madhusmita Behera, Sagar Lonial, et al.
Acta Haematologica|May 12, 2024
Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory DrugsJulie Barberio, Timothy L Lash, Ajay K Nooka, et al.
Oncotarget|August 4, 2016
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylationShardule P Shah, Ajay K Nooka, David L Jaye, et al.
Journal of Oncology Practice|July 12, 2018
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and ElotuzumabAjay K Nooka, Charise Gleason, Marva Ollivierre Sargeant, et al.
Hemasphere|September 25, 2025
The impact of reduced dosing frequency of elranatamab on patient-reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-3Nizar J Bahlis, Ajay K Nooka, Marco DiBonaventura, et al.
Pageof 15